07:00 , Jun 20, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) BRAF Patient studies suggest Zelboraf vemurafenib could help treat BRAF V600E mutant MM. In samples from patients with MM, the BRAF V600E...
07:00 , May 27, 1997 |  BC Week In Review  |  Clinical News

Thalidomide data

A report in the New England Journal of Medicine showed that four weeks of the drug completely healed aphthous ulcers in 55 percent of patients with HIV, compared to 7 percent healing for patients on...
07:00 , Aug 14, 1995 |  BC Week In Review  |  Company News

Andrulis Pharmaceuticals Corp., University of Verona deal

Andrulis and the University of Verona will study the ability of thalidomide to inhibit the production of cytokines by immune system cells of the brain. The Verona scientists hypothesize that inflammatory cytokines and free radicals...
07:00 , May 30, 1995 |  BC Week In Review  |  Clinical News

Andrulis Pharmaceuticals Corp. regulatory update

Andrulis's thalidomide product received Orphan Drug designation to prevent and treat recurrent aphthous ulcers (canker sores) in severely, terminally immunocompromised patients. Privately held Andrulis (Beltsville, Md.) is conducting a pivotal Phase II/III trial in canker...
07:00 , Apr 17, 1995 |  BC Week In Review  |  Clinical News

Andrulis Pharmaceuticals Corp. regulatory update

The Beltsville, Md., company received U.S. Patent No. 5,405,855 covering the use of thalidomide to treat non-insulin-dependent diabetes mellitus. By blocking factors that cause insulin resistance, thalidomide may promote increased glucose metabolism, Andrulis said. Andrulis...